RxDoctor Payments Data

Deanna Zimkus, PA

Physician Assistant · Wolcott, CTNPI 1710211370

Payments from drug & device makers

$3,253in general payments, 2019–2025

Across 122 payments — averaging $26.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$365
  • Galderma Laboratories, L.p.$275
  • Johnson & Johnson$270
  • GSK$246
  • UCB, Inc.$237
  • plus $758 from 10 others

What the payments were for

  • Food & beverage$3,17398%
  • Education$802%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,253 in reported general payments places this provider in the 90th percentile of 1,795 physician assistant providers in Connecticut.

See all physician assistant providers in Connecticut

Medicare billing

Part B allowed, 2024
$90,698
Medicare patients
408
Services billed
1,536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa19$395,523
Dupixent PenDupilumab40$158,313
Dupixent SyringeDupilumab35$131,250
OtezlaApremilast16$105,715
OpzeluraRuxolitinib Phosphate15$30,099
Doxycycline Ir-DrDoxycycline Monohydrate12$6,488
Clobetasol Propionate110$5,176
Ivermectin20$4,172
Metronidazole61$3,896
Betamethasone Diprop AugmentedBetamethasone Dipropionate35$3,489
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc93$3,211
Gentamicin Sulfate41$3,181
Tacrolimus14$2,837
Clindamycin Phosphate83$2,523
Tretinoin26$2,359

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$365$105,71516 claims
Incyte CorporationOpzelura$23$30,09915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,795 physician assistant providers in Connecticut.

Other physician assistant in Wolcott

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →